that induces angiogenesis in the mammal.

- 13. (Amended) The method of claim 7 wherein the antigen is [substantially] purified.
- 17. (Amended) The method of claim 1 wherein the immunogen is expressed on an antigen-presenting cell that is not native to the mammal.
- 20. (Amended) The method of claim 1 wherein the [a] molecule that induces angiogenesis is FLK-1.
- 21. (Amended) The method of claim 1 wherein the [a] molecule that induces angiogenesis is KDR.

(Amended) The method of claim 1 wherein the [a] molecule that induces angiogenesis is FLT-1.

- 23. (Amended) The method of claim 1 wherein the [a] molecule that induces angiogenesis is VEGF.
- 56. (Amended) A method of inhibiting an unwanted angiogenic condition in a mammal in need thereof comprising [treating] <u>administering to</u> the mammal [with] an effective amount of a vector that expresses an immunogen that causes an immune response against a molecule that induces angiogenesis in the mammal.

REMARKS

Amended Claims

Claims 1, 13, 17, 20, 21, 23 and 56 have been amended. Entry of the amended claims, and reconsideration of the application as amended, is respectfully requested.